PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩125 per share · Prices as of the 2026-10-02 close
Bukwang Pharm posted its largest-ever revenue and a return to profit in 2025, but margins wobbled again in 2026, leaving the integration of Korea Union Pharm and Contera Pharma's pipeline results as the key swing factors ahead.
2025 consolidated revenue reached KRW 200.7 billion, the first time topping KRW 200 billion, with operating profit surging to KRW 14.16 billion from KRW 1.6 billion a year earlier, and net income turning positive.
Operating margin slipped back to around 2% in both the first and second quarters of 2026, as FX-driven cost pressure, expanded outsourced production, and new-product marketing spend weighed on profitability.
In May 2026 the company completed the acquisition of a 75.14% stake in Korea Union Pharm, aiming to expand solid-dose, injectable, and antibiotic production capacity to resolve chronic stock-out issues.
Danish subsidiary Contera Pharma's Parkinson's morning akinesia candidate 'CP-012' is in global Phase 2 trials, with preliminary licensing discussions underway with several global pharmaceutical companies.
The largest shareholder is OCI Holdings, and the company reinforced its balance sheet with an KRW 89.3 billion rights offering in July 2025.
Bukwang Pharm is a finished-dosage pharmaceutical company handling both prescription (ETC) and over-the-counter (OTC) products, with key items including diabetic neuropathy treatments Dexid and Thioctacid, the antipsychotic Latuda, the liver treatment Legadex, and cold remedies Ferrova and Tacenol.
The core driver of recent growth has been the central nervous system (CNS) division, as Latuda has rapidly gained market traction, pushing that segment's revenue up more than 90% year over year.
In the first quarter of 2026 the company launched the insomnia treatment Circadep sustained-release tablets and the epilepsy treatment Brifil tablets, broadening its CNS lineup.
New drug development is centered on Danish subsidiary Contera Pharma, acquired in 2014, with the Parkinson's morning akinesia candidate CP-012 and an RNA therapeutics platform serving as the two main pillars.
In May 2026 the company acquired a 75.14% stake in Korea Union Pharm, which had been under court receivership, via a third-party rights offering, becoming its largest shareholder—a move aimed largely at securing production infrastructure, including cephalosporin antibiotic capacity, to address chronic stock-out issues in its own essential medicines.
In the domestic finished-dosage market, Bukwang competes against large players such as Chong Kun Dang, Yuhan, and JW Pharmaceutical along with numerous generic and improved-drug makers, positioning itself as a relatively mid-sized company differentiated by its CNS and chronic-disease-focused portfolio.
Its largest shareholder is OCI Holdings, and since that change the company has pursued a shift toward concentrated R&D and new-drug-centered operations. On the commercial side, a five-product co-promotion agreement with Korea Servier is intended to expand prescriptions in chronic disease areas.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩42.6B | ₩2B | 4.7% |
| 2025Q3 | ₩47.8B | ₩1B | 2.0% |
| 2025Q4 | ₩62.5B | ₩8.2B | 13.0% |
| 2026Q1 | ₩47.8B | ₩1.1B | 2.3% |
| 2026Q2 | ₩57B | ₩1.4B | 2.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩190.9B | -₩200M | -₩2.5B | −0.1% | −0.9% | 47.5% |
| 2023 | ₩125.9B | -₩37.5B | -₩31.3B | −29.8% | −13.8% | 83.1% |
| 2024 | ₩160.1B | ₩1.6B | -₩2.6B | 1.0% | −1.1% | 52.9% |
| 2025 | ₩200.7B | ₩14.2B | ₩12.6B | 7.1% | 3.7% | 39.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Consolidated revenue for 2025 rose to KRW 200.7 billion from KRW 160.1 billion a year earlier, operating profit jumped to KRW 14.16 billion from KRW 1.6 billion, and net income attributable to owners swung to a profit of KRW 12.56 billion from a loss of KRW 2.64 billion in 2024.
This marks a clear recovery two years after the deep 2023 loss, when revenue was KRW 125.9 billion and the operating loss reached KRW 37.5 billion, an operating margin of negative 29.8%. That recovery, however, did not carry through smoothly into 2026.
First-quarter 2026 revenue was KRW 47.78 billion with operating profit of just KRW 1.1 billion, a narrower margin than the second quarter of 2025 (revenue KRW 42.58 billion, operating profit KRW 2.01 billion) and the third quarter (revenue KRW 47.81 billion, operating profit KRW 0.98 billion), which the company attributed mainly to higher manufacturing costs from expanded outsourced production aimed at preventing stock-outs of essential medicines.
The fourth quarter of 2025 delivered the strongest quarterly profit, with revenue of KRW 62.51 billion and operating profit of KRW 8.16 billion, but by the second quarter of 2026 revenue grew to KRW 56.99 billion while operating profit came in at only KRW 1.41 billion and net income attributable to owners at KRW 1.4 billion, again showing profit growth lagging revenue growth.
Factors cited for the margin softness include higher raw-material and finished-goods import costs from a stronger exchange rate, increased outsourcing expenses tied to building automated production lines, new-product marketing spend, and clinical costs for Contera Pharma's CP-012.
Over the trailing four quarters (Q3 2025 through Q2 2026), revenue fluctuated between roughly KRW 47 billion and KRW 63 billion per quarter while operating profit ranged from about KRW 1 billion to KRW 8 billion, indicating that the annual return to profitability has not yet translated into a consistent quarterly pattern.
On the balance-sheet side, the debt ratio fell from 83.1% in 2023 to 39.7% in 2025, largely reflecting a jump in total equity from KRW 234.3 billion in 2023 to KRW 340.9 billion in 2025 following a large rights offering in July 2025.
The domestic finished-dosage pharmaceutical industry is shaped by rising demand for chronic disease and CNS treatments amid an aging population, alongside ongoing cost pressure from raw-material supply instability and currency fluctuations.
In the CNS and chronic-disease segment where Bukwang competes, first-quarter 2026 prescription data from UBIST showed overall ETC prescriptions growing 8.7% year over year, with the CNS division growing 36%, well above the broader market average.
This reflects expanding prescriptions for new products such as Latuda, and the company said it expects CNS revenue contribution to become more pronounced from the second quarter onward.
At the same time, the broader industry has faced years of chronic essential-medicine stock-out issues, prompting small and mid-sized pharmaceutical companies, including Bukwang, to respond through expanded outsourced production or acquisitions of manufacturing capacity.
In the Parkinson's disease treatment field, existing therapies remain limited to immediate- or extended-release formulations, leaving a reported gap in treatments specifically targeting morning akinesia symptoms.
In terms of competitive positioning, Bukwang is smaller in scale than large pharmaceutical companies such as Chong Kun Dang and Yuhan, but seeks differentiation through its CNS- and chronic-disease-focused product lineup and Contera Pharma's pipeline.
The company has outlined several initiatives aimed at improving results in the second half of 2026.
On the Korea Union Pharm integration, it is working to normalize sales and production operations while discussing a restructuring of CSO commission arrangements, and has set a target of raising the cephalosporin antibiotic production line utilization rate from around 100% to approximately 120%.
Contera Pharma is proceeding with a spin-off of its RNA therapeutics discovery platform into a separate entity, having filed for preliminary approval with Danish tax authorities, with the new entity expected to be established in the fourth quarter of 2026.
The Parkinson's disease candidate CP-012 is undergoing global Phase 2 trials in the United States and Europe, and the company said it is continuing preliminary business-development discussions with multiple global pharmaceutical companies ahead of the trial readout.
The antipsychotic Latuda is in preparation for an Investigational New Drug (IND) submission to the Ministry of Food and Drug Safety to add a major depressive disorder (MDD) indication.
On the commercial side, expanded chronic-disease prescriptions through the co-promotion agreement with Korea Servier, along with growing sales contributions from new products Circadep and Brifil, are cited as swing factors for second-half results.
However, whether these plans translate into actual profitability improvement remains contingent on integration costs from Korea Union Pharm, exchange-rate trends, and the pace of clinical development.
Bukwang's share price has moved through both premium and discount phases relative to net asset value as the company transitioned from a large 2023 loss to profitability in 2024–2025.
It currently trades at a certain premium to net asset value, which can be read as partly reflecting the 2025 turnaround and expectations around its drug pipeline.
Relative to the size of its earnings, the market's valuation benchmark appears to have risen compared with the deep-loss period of 2023, and given the volatility in recent quarterly profits, this benchmark could adjust again depending on how coming quarters play out.
The dividend yield runs below the sector average, consistent with the company having prioritized funding for production capacity expansion and drug development over earnings stability in recent years.
Sangsangin Securities, in a report dated March 31, 2026, discussed Bukwang's shift toward a drug-development-focused company on the basis of Contera Pharma's RNA platform, though that report did not provide a specific target price or investment rating.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
Consolidated 2025 revenue crossed KRW 200 billion for the first time in the company's history, reaching KRW 200.7 billion, with operating profit rising sharply to KRW 14.16 billion.
The growth engine has been the CNS division, where the antipsychotic Latuda has gained rapid market traction, pushing segment revenue up more than 90% year over year. That momentum continued into the first quarter of 2026, with CNS prescriptions growing 36%.
To address a years-long essential-medicine stock-out problem, Bukwang acquired a 75.14% stake in Korea Union Pharm in May 2026. This is expected to expand solid-dose, injectable, and antibiotic production capacity, with a stated target of lifting the cephalosporin line's utilization rate from 100% to around 120%. If production normalizes, cost pressure from expanded outsourcing could ease over time.
Contera Pharma's CP-012, a reportedly first-in-class oral delayed-release candidate targeting Parkinson's morning akinesia, is in global Phase 2 trials.
Several global pharmaceutical companies are said to be conducting preliminary business-development discussions ahead of reviewing the trial data before deciding on contracts. Contera Pharma's RNA therapeutics platform is also being spun off into a separate entity in an effort to build its own value.
Despite the full-year 2025 return to profit, operating margin stayed around 2% in both the first and second quarters of 2026, noticeably lower than year-earlier levels.
The company cited a stronger exchange rate, expanded outsourced production, new-product marketing spend, and clinical costs, but it remains uncertain whether these pressures will ease structurally.
Quarterly profit volatility has been high, so the annual recovery trend has not repeated consistently on a quarterly basis.
Korea Union Pharm emerged from court receivership, and post-acquisition integration tasks remain, including normalizing its CSO commission structure and improving utilization rates.
Current liabilities reportedly surged from KRW 35.3 billion to KRW 117.8 billion in 2025, a decade-high level, meaning the expansion strategy could still translate into financial strain. If cost management during integration falls short, the benefits of the capacity expansion could be delayed.
Contera Pharma previously invested roughly KRW 100 billion over a decade in JM-010, a Parkinson's dyskinesia candidate that failed to meet its endpoint in European Phase 2 trials, leading to the discontinuation of U.S. trials as well.
The pipeline focus has since shifted to CP-012, but drug development inherently carries failure risk at every clinical stage. A pipeline concentrated in a small number of candidates means valuation assessments can swing considerably based on the outcome of any single trial.
The debt ratio spiked to 83.1% in 2023, and current liabilities reportedly increased substantially in 2025.
While the large July 2025 rights offering improved the balance sheet, ongoing funding needs for the Korea Union Pharm integration and drug development programs such as CP-012 could raise the possibility of additional capital raises. Currency fluctuations also directly affect import costs for raw materials and finished products.
CP-012 is still only at the global Phase 2 stage, with multiple steps remaining before Phase 3 and regulatory approval. As with the earlier failure of JM-010, unexpected outcomes remain possible at any stage.
With organizational changes such as the RNA platform spin-off underway, whether R&D resources become diluted is also worth monitoring.
Korea Union Pharm emerged from receivership, and normalization tasks such as CSO commission restructuring and utilization improvement remain in progress.
Although its board has been reorganized around Bukwang personnel, whether actual production and sales synergies materialize as planned needs to be confirmed over time. Integration costs and schedule delays could add to near-term earnings volatility.
Third-quarter 2026 earnings release - the first quarter with Korea Union Pharm results substantially reflected, a chance to check whether operating margin recovers and the scale of integration costs.
Expected completion of Contera Pharma's new RNA entity spin-off - worth checking the progress of the spin-off and subsequent funding or partnering plans.
Whether an IND is submitted to add an MDD indication for the antipsychotic Latuda - indication expansion would tie into further CNS revenue contribution.
The timing of CP-012's global Phase 2 topline data readout and subsequent progress in licensing negotiations with global pharmaceutical companies.
Whether Korea Union Pharm's cephalosporin line reaches its 120% utilization target and the outcome of CSO commission renegotiations.
Bukwang Pharm has clearly passed an inflection point with its 2025 revenue crossing KRW 200 billion and return to profit, yet operating margin slipping back to around 2% in the first half of 2026 leaves open questions about the quality and durability of that profitability.
Prescription growth in the CNS division and Latuda's market traction are positive signals, but cost items such as exchange rates and outsourced production expenses continue to add volatility.
The Korea Union Pharm acquisition is meaningful in that it expands production infrastructure to address a chronic stock-out problem, but the sharp rise in current liabilities and integration costs stand out as factors testing that balance.
On the pipeline side, CP-012's global Phase 2 trial and the spin-off of Contera Pharma's RNA platform offer medium- to long-term optionality, though the earlier failure of JM-010 is a reminder of the inherent uncertainty in drug development.
Ultimately, the company's next phase hinges on two axes: the pace of financial and operational efficiency gains from the Korea Union Pharm integration, and the outcome of CP-012's clinical trials.
Ahead of any investment decision, it appears worthwhile to track both the upcoming third-quarter results and the schedule for clinical data releases.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.